Provided by Tiger Trade Technology Pte. Ltd.

Incyte

117.14
-4.2100-3.47%
Post-market: 116.50-0.6400-0.55%19:30 EDT
Volume:2.36M
Turnover:279.69M
Market Cap:23.74B
PE:14.92
High:121.22
Open:120.47
Low:117.00
Close:121.35
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.60
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.74
PE(LYR):18.27

Loading ...

FDA: Approves Atebrioz (Zilurgisertib) for Fibrodysplasia Ossificans Progressiva in Adults & Pediatric Patients 12 Years + - Website

THOMSON REUTERS
·
Sep 26

FDA : Atebrioz Recommended Dosage 100 Mg Once Daily

THOMSON REUTERS
·
Sep 26

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 23

Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says

MT Newswires Live
·
Sep 22

Incyte Price Target Maintained with a $109.00/Share by RBC Capital

Dow Jones
·
Sep 22

Incyte Posts 24-Week TRuE-AD4 Data on Long-Term Safety of Ruxolitinib Cream in Moderate Atopic Dermatitis at EADV 2026

Reuters
·
Sep 22

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

Incyte Expands Skin Diseases Treatment Partnership in Australia

MT Newswires Live
·
Sep 21

Specialised Therapeutics expands partnership with Incyte to include Opzelura

TIPRANKS
·
Sep 21

AFLAC, CME, Incyte, Box, Five Below Insider Shake-Up

TIPRANKS
·
Sep 19

Incyte Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 18

Incyte R&D President Pablo J. Cagnoni Disposes of 23,218 Common Shares Worth $2.8 Million

Reuters
·
Sep 18

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 17

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 16

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 11

Incyte Says Follicular Lymphoma Treatment Minjuvi Being Funded in Ontario Via FAST Program

MT Newswires Live
·
Sep 10

Incyte Announces Funding of Minjuvi® (Tafasitamab) for Patients with Relapsed or Refractory Follicular Lymphoma Through Ontario's Fast Program

THOMSON REUTERS
·
Sep 10

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 09

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 02

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 01